AB Corporate Bond ETF (NASDAQ:EYEG) Short Interest Update

AB Corporate Bond ETF (NASDAQ:EYEG) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 655 shares, a growth of 568.4% from the July 15th total of 98 shares. Based on an average daily volume of 295 shares, the days-to-cover ratio is currently 2.2 days. Approximately 0.0% of the company’s shares are short sold.

AB Corporate Bond ETF Trading Up 0.2%

NASDAQ EYEG traded up $0.06 during trading hours on Wednesday, hitting $34.57. 259 shares of the company’s stock were exchanged, compared to its average volume of 252. The business’s 50 day moving average is $34.98 and its 200-day moving average is $35.30. AB Corporate Bond ETF has a 12-month low of $34.46 and a 12-month high of $36.63. The firm has a market capitalization of $27.66 million, a P/E ratio of -20.58 and a beta of 0.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.07.

AB Corporate Bond ETF Increases Dividend

The business also recently disclosed a monthly dividend, which was paid on Thursday, August 6th. Stockholders of record on Monday, August 3rd were paid a dividend of $0.1427 per share. The ex-dividend date of this dividend was Monday, August 3rd. This represents a c) dividend on an annualized basis and a dividend yield of 5.0%. This is an increase from AB Corporate Bond ETF’s previous monthly dividend of $0.14. AB Corporate Bond ETF’s dividend payout ratio is currently -102.38%.

Institutional Investors Weigh In On AB Corporate Bond ETF

A hedge fund recently raised its position in AB Corporate Bond ETF stock. Jane Street Group LLC boosted its stake in shares of AB Corporate Bond ETF (NASDAQ:EYEG) by 166.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,741 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,839 shares during the period. Jane Street Group LLC owned approximately 2.10% of AB Corporate Bond ETF worth $563,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.